Beijing Kawin Technology Co., Ltd. (688687)
Market Closed
11 Aug, 06:57
SSE SSE Primary ¥
17. 70
-0.25
-1.3928%
¥
4.16B Market Cap
- P/E Ratio
1% Div Yield
4.06M Volume
- Eps
¥ 17.95
Previous Close Want to track 688687 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
688687 closed today lower at ¥17.7, a decrease of -1.3928% from yesterday's close, completing a monthly increase of 8.4559% or ¥1.38. Over the past 12 months, 688687 stock lost -28.5714%.
688687 pays dividends to its shareholders, with the most recent payment made on Jun 03, 2026. The next estimated payment will be in In 9 months on Jun 03, 2027 for a total of ¥0.25.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
688687 Chart
People also search for
Beijing Kawin Technology Co., Ltd. (688687) FAQ
What is the stock price today?
The current price is ¥17.70.
On which exchange is it traded?
Beijing Kawin Technology Co., Ltd. is listed on SSE.
What is its stock symbol?
The ticker symbol is 688687.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1%.
What is its market cap?
As of today, the market cap is 4.16B.
Has Beijing Kawin Technology Co., Ltd. ever had a stock split?
No, there has never been a stock split.
Beijing Kawin Technology Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Desheng Zhou CEO | SSE Exchange | CNE1000054C3 ISIN |
| CN Country | 584 Employees | 3 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Beijing Kawin Technology Share-Holding Co., Ltd. is a prominent player in the pharmaceutical industry, focusing on the research, development, and manufacturing of medications tailored to treat liver diseases predominantly within China. Since its inception in 2008, the company has not only made notable contributions to liver disease treatment but has also established strategic partnerships with significant financiers and investors such as Legend Capital, Haitong Capital, and Cybernaut. Based in Beijing, China, the firm is recognized for its innovation in pharmaceutical products and commitment to enhancing healthcare.
Products and Services
- Recombinant Human Interferon Alfa-2b Injection: A biological medication used primarily in the treatment of various types of viral hepatitis, showcasing Beijing Kawin Technology's dedication to combatting liver diseases through advanced biotechnological methods.
- Vaginal Effervescent Tablets: Designed for women's health, these tablets are an innovative product that signifies the company's commitment to broadening its product range and catering to a wide range of healthcare needs.
- Coblopasvir Hydrochloride Capsules: An antiviral medication aimed at treating hepatitis C, these capsules represent the cutting-edge research and development efforts of Beijing Kawin Technology in addressing chronic liver diseases.
- Sofosbuvir Tablets: Another antiviral treatment option for hepatitis C, sofosbuvir tablets underline the company’s focus on providing groundbreaking solutions for complex liver conditions.
- Compound Glycyrrhizin: This product highlights Beijing Kawin Technology's use of traditional medicine knowledge combined with modern pharmaceutical practices to create treatments that support liver function and health.
Contact Information
Address: Building 3, No. 6, Rongjing East Street, Beijing, China, 100176
Phone: 86 10 6789 2271
Website: https://www.kawin.com.cn
